(Q74692829)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

A risk-benefit assessment of irinotecan in solid tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

L L Siu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

E K Rowinsky

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

395-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9638386%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00002018-199818060-00002

12 November 2019

exact match

0 references

cites work

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

1 reference

12 December 2020

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

1 reference

12 December 2020

Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system

1 reference

12 December 2020

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

12 December 2020

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

12 December 2020

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

1 reference

12 December 2020

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

12 December 2020

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Phase I clinical study of CPT-11. Research group of CPT-11

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

12 December 2020

CPT-11-induced cholinergic effects in cancer patients

1 reference

12 December 2020

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

1 reference

12 December 2020

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors

1 reference

12 December 2020

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse

1 reference

12 December 2020

An early phase II study of CPT-11 in primary lung cancer

1 reference

12 December 2020

Pharmacogenetics in cancer etiology and chemotherapy

1 reference

12 December 2020

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

12 December 2020

A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers

1 reference

12 December 2020

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

1 reference

12 December 2020

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

1 reference

12 December 2020

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

1 reference

12 December 2020

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer

1 reference

12 December 2020

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

1 reference

12 December 2020

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

12 December 2020

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

12 December 2020

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

1 reference

12 December 2020

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

12 December 2020

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

1 reference

12 December 2020

Action of camptothecin on mammalian cells in culture

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

The current status of camptothecin analogues as antitumor agents

1 reference

12 December 2020

A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11

1 reference

12 December 2020

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1 reference

12 December 2020

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

12 December 2020

Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair

1 reference

12 December 2020

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

12 December 2020

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

12 December 2020

A phase-I study of cpt-11, weekly bolus 5-fu and leucovorin in patients with metastatic cancer

1 reference

12 December 2020

Topoisomerase I inhibitors: review and update

1 reference

12 December 2020

Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L 1210 leukemia

1 reference

12 December 2020

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]

1 reference

12 December 2020

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11

1 reference

12 December 2020

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

12 December 2020

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

1 reference

12 December 2020

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

12 December 2020

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

12 December 2020

The effects of camptothecin on mammalian DNA

1 reference

12 December 2020

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

12 December 2020

Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion

1 reference

12 December 2020

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

12 December 2020

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

12 December 2020

Treatment of malignant melanoma with camptothecin (NSC-100880)

1 reference

12 December 2020

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy

1 reference

12 December 2020

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer

1 reference

12 December 2020

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer

1 reference

12 December 2020

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

12 December 2020

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons

1 reference

12 December 2020

Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase

1 reference

12 December 2020

Effects of camptothecin on the breakage and repair of DNA during the cell cycle

1 reference

12 December 2020

A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group

1 reference

12 December 2020

[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer]

1 reference

12 December 2020

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1 reference

12 December 2020

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

12 December 2020

[A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]

1 reference

12 December 2020

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1 reference

12 December 2020

Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice

1 reference

12 December 2020

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients

1 reference

12 December 2020

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

12 December 2020

Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent

1 reference

12 December 2020

A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer

1 reference

12 December 2020